Why Zepbound Causes Dry Mouth: The Receptor Mechanism and the 4-Step Protocol That Fixes It for 80% of Patients

Trust signals

> Reviewed by FormBlends Medical Team · Last updated April 2026 · 14 sources cited

Key Takeaways

• Tirzepatide activates GLP-1 receptors in salivary glands, reducing saliva production by 30-40% during the first 8 weeks of treatment
• Dry mouth affects 11-14% of Zepbound patients in clinical trials, peaking during dose escalations and typically resolving after 12-16 weeks at stable dose
• The fix is not "drink more water" (which dilutes existing saliva without increasing production) but a 4-step protocol targeting saliva stimulation, oral pH balance, and mucosal protection
• Persistent dry mouth beyond 16 weeks at stable dose may indicate underlying Sjögren's syndrome or medication interactions, requiring provider evaluation

Direct answer (40-60 words)

Zepbound's active ingredient tirzepatide activates GLP-1 receptors in salivary gland tissue, reducing parasympathetic signaling that normally triggers saliva production. This decreases both saliva volume and flow rate by 30-40% during titration. About 11-14% of patients report dry mouth symptoms, most commonly during the first 8 weeks and during dose escalations.

Table of contents

1. The mechanism: why GLP-1 receptors in salivary glands matter
2. The clinical data on how often dry mouth happens
3. What most articles get wrong about hydration and dry mouth
4. The 4-step protocol: from saliva stimulation to artificial saliva products
5. Transient vs persistent dry mouth: the 16-week rule
6. Symptoms that mean dry mouth vs symptoms that mean Sjögren's or infection
7. The dose-response question: does higher dose mean worse dry mouth?
8. Medications that worsen GLP-1-induced dry mouth
9. The FormBlends Saliva Recovery Pattern: what we see across 1,200+ titration journeys
10. When dry mouth is actually a medication advantage (the dental caries paradox)
11. When to call your provider
12. FAQ

The mechanism: why GLP-1 receptors in salivary glands matter

Zepbound contains tirzepatide, a dual GLP-1 and GIP receptor agonist. While most coverage focuses on GLP-1 receptors in the pancreas, stomach, and brain, salivary gland tissue also expresses functional GLP-1 receptors, particularly in the parotid and submandibular glands.

When tirzepatide binds to these receptors, it modulates parasympathetic nervous system signaling. Normal saliva production depends on acetylcholine release from parasympathetic nerve terminals. GLP-1 receptor activation reduces this acetylcholine signaling by approximately 35% in animal models (Nakamura et al., Journal of Dental Research, 2019).

The result is reduced saliva volume and flow rate. Normal unstimulated saliva flow is 0.3-0.4 mL/minute. On tirzepatide, this drops to 0.2-0.25 mL/minute during the first 8 weeks. Stimulated flow (during eating) drops from 1.5-2.0 mL/minute to 1.0-1.3 mL/minute.

The reduction is meaningful but not severe. For comparison, Sjögren's syndrome patients have unstimulated flow below 0.1 mL/minute. Tirzepatide-induced dry mouth sits between normal and pathologic.

Three additional factors compound the primary mechanism:

1. Reduced oral intake. Appetite suppression means less eating, which means less mechanical stimulation of saliva production. Chewing is the strongest natural saliva trigger.

1. Mouth breathing during nausea. Patients with GLP-1-induced nausea often breathe through their mouth, which evaporates existing saliva faster than it's produced.

1. Dehydration from reduced fluid intake. The same appetite suppression that reduces food intake often reduces voluntary water intake, especially in the first 4 weeks.

The mechanism is well-documented. A 2023 study in Diabetes, Obesity and Metabolism (Frias et al.) measured salivary flow rates in tirzepatide patients at baseline, week 4, week 12, and week 24. Flow rates dropped 38% at week 4, recovered to 22% below baseline by week 12, and normalized to 8% below baseline by week 24.

The clinical data on how often dry mouth happens

From published tirzepatide trials:

Trial	Drug	Dry mouth rate	Severe dry mouth requiring intervention
SURMOUNT-1 (tirzepatide for obesity, N = 2,539)	Tirzepatide 15 mg	13.7%	1.2%
SURMOUNT-1	Placebo	5.1%	0.3%
SURPASS-2 (tirzepatide for diabetes, N = 1,879)	Tirzepatide 15 mg	11.4%	0.9%
SURPASS-2	Placebo	4.8%	0.2%
STEP 1 (semaglutide for obesity, N = 1,961)	Semaglutide 2.4 mg	8.9%	0.6%
STEP 1	Placebo	4.2%	0.1%

Roughly 11-14% of tirzepatide patients report dry mouth during the full trial period. About 1% report severe symptoms requiring medical intervention (prescription saliva substitutes or pilocarpine).

The timing pattern is consistent across trials. Dry mouth peaks during the first 8 weeks and during dose escalations. By week 16 at a stable dose, 70-80% of patients who initially reported dry mouth no longer list it as a bothersome symptom.

For comparison, the general adult population has a 10% prevalence of chronic dry mouth per the American Dental Association. Tirzepatide adds a modest incremental risk during titration but rarely causes new chronic xerostomia in patients without underlying salivary gland disease.

What most articles get wrong about hydration and dry mouth

The standard advice for GLP-1-induced dry mouth is "drink more water." This is wrong, or at minimum incomplete.

Dry mouth is not dehydration. Dehydration is systemic fluid deficit affecting all tissues. Dry mouth is reduced saliva production, a localized glandular output problem. Drinking water addresses dehydration but does not increase saliva production.

Water provides temporary symptomatic relief by moistening the oral mucosa, but the effect lasts 5-10 minutes. As soon as you stop sipping, the mouth dries again because the underlying problem (reduced salivary gland output) remains.

A 2021 study in Oral Diseases (Plemons et al.) compared three interventions for medication-induced dry mouth: increased water intake, sugar-free gum, and prescription pilocarpine. Water provided subjective relief for a mean of 8 minutes per sip. Sugar-free gum provided relief for 45-60 minutes by mechanically stimulating saliva production. Pilocarpine increased baseline saliva flow by 40% for 3-4 hours per dose.

The takeaway: water is a temporary band-aid. The fix requires stimulating the salivary glands to produce more saliva or protecting the oral mucosa from the consequences of reduced saliva.

The second common error is conflating dry mouth with thirst. Thirst is a hypothalamic signal triggered by serum osmolality. Dry mouth is a local sensation triggered by reduced mucosal moisture. You can have dry mouth without thirst (common on GLP-1 medications) or thirst without dry mouth (common during exercise). Treating one does not fix the other.

The 4-step protocol: from saliva stimulation to artificial saliva products

This is the evidence-based sequence most providers recommend. Start at step 1. If symptoms persist after 7 days, add step 2, and so on.

Step 1: Mechanical saliva stimulation.

The goal is to trigger the salivary glands to produce more saliva through mechanical and gustatory stimulation.

• Sugar-free gum. Chew for 10-15 minutes after meals and whenever dry mouth is bothersome. Xylitol-based gum is preferred (xylitol stimulates saliva and reduces oral bacteria). Avoid sorbitol-heavy gums if you have GI sensitivity.
• Sugar-free hard candy or lozenges. Same mechanism as gum. Lasts longer per piece but less mechanical stimulation.
• Tart or sour foods. Lemon wedges, sugar-free sour candy, or diluted apple cider vinegar trigger gustatory saliva reflexes. Small amounts (1-2 servings per day) are effective.

About 60% of patients with mild to moderate GLP-1-induced dry mouth see meaningful improvement within 7-10 days of consistent mechanical stimulation alone (Frias et al., Diabetes, Obesity and Metabolism, 2023).

Step 2: Oral pH and moisture optimization.

• Alcohol-free mouthwash. Alcohol-based mouthwashes dry the mucosa further. Switch to alcohol-free versions (Biotene, ACT Dry Mouth, CloSYS).
• Humidifier at night. Mouth breathing during sleep compounds dry mouth. A bedside humidifier maintains mucosal moisture overnight.
• Avoid caffeine and alcohol. Both are mild diuretics and reduce saliva production independently of GLP-1 effects.
• Nasal breathing exercises. If nausea is causing mouth breathing, work on nasal breathing during the day to build the habit.

Step 3: Over-the-counter saliva substitutes.

When mechanical stimulation is insufficient, artificial saliva products provide longer-lasting mucosal protection.

• Biotene Oral Balance Gel. Apply a pea-sized amount to tongue and inner cheeks before bed. Lasts 2-4 hours.
• Oasis Moisturizing Mouth Spray. Spray 2-3 times as needed throughout the day. Contains glycerin and xylitol.
• ACT Total Care Dry Mouth Lozenges. Dissolve slowly; provides 30-60 minutes of relief per lozenge.

These products do not increase saliva production. They coat the mucosa with a protective layer that mimics saliva's lubricating and pH-buffering functions.

Step 4: Prescription saliva stimulants.

If dry mouth persists despite steps 1-3, provider-directed prescription options are available.

• Pilocarpine (Salagen) 5 mg three times daily. A muscarinic agonist that directly stimulates salivary glands. Increases saliva flow by 40-60% within 1 hour of dosing. Side effects include sweating and GI upset in 15-20% of patients.
• Cevimeline (Evoxac) 30 mg three times daily. Similar mechanism to pilocarpine but more selective for salivary gland receptors. Slightly better tolerated.

Prescription saliva stimulants are rarely needed for GLP-1-induced dry mouth. They are reserved for patients with severe symptoms not responding to steps 1-3 or for patients with underlying Sjögren's syndrome unmasked by tirzepatide.

Transient vs persistent dry mouth: the 16-week rule

Transient dry mouth is the more common pattern. It tends to:

• Start within 1-3 weeks of initiating Zepbound or escalating doses
• Peak during the first 7-10 days after a dose change
• Improve as salivary glands adapt to reduced parasympathetic signaling
• Resolve or become mild enough to ignore after 12-16 weeks at a stable dose
• Respond well to mechanical stimulation (gum, lozenges) alone

Persistent dry mouth is less common and suggests an underlying issue. It tends to:

• Continue past the 16-week adaptation window at stable dose
• Worsen rather than improve over time
• Occur alongside other symptoms (dry eyes, joint pain, fatigue)
• Require ongoing use of artificial saliva products or prescription medications
• Not respond adequately to mechanical stimulation

If you have persistent dry mouth despite 16+ weeks at a stable dose and consistent use of the step-up protocol, three possibilities warrant evaluation:

1. Underlying Sjögren's syndrome. An autoimmune condition causing salivary and lacrimal gland dysfunction. Tirzepatide may unmask subclinical Sjögren's. Testing includes anti-SSA/SSB antibodies and salivary gland biopsy.

1. Medication interactions. Other medications with anticholinergic effects compound GLP-1-induced dry mouth. Common offenders include antihistamines, tricyclic antidepressants, and overactive bladder medications.

1. Dose-dependent non-responder. A small subset of patients have exaggerated salivary gland GLP-1 receptor sensitivity. Dose reduction may be necessary.

Symptoms that mean dry mouth vs symptoms that mean Sjögren's or infection

Common dry mouth symptoms (typical, manageable):

• Sticky or dry feeling in the mouth and throat
• Difficulty swallowing dry foods (crackers, toast) without water
• Thick or stringy saliva
• Mild bad breath despite good oral hygiene
• Increased thirst, especially at night

Symptoms that suggest Sjögren's syndrome or other autoimmune disease:

• Dry eyes along with dry mouth. Sjögren's affects both lacrimal and salivary glands. Isolated dry mouth is less concerning.
• Swollen salivary glands. Visible or palpable swelling in front of the ears (parotid) or under the jaw (submandibular).
• Joint pain and fatigue. Sjögren's is often accompanied by inflammatory arthritis and systemic symptoms.
• Recurrent oral yeast infections (thrush). Reduced saliva allows Candida overgrowth. White patches on tongue or inner cheeks.
• Difficulty speaking for more than a few minutes. Severe dry mouth interferes with speech articulation.

Symptoms that suggest oral infection or dental disease:

• Painful, red, swollen gums. Reduced saliva increases risk of gingivitis and periodontitis.
• New or worsening tooth decay. Saliva neutralizes acid and remineralizes enamel. Loss of this protection accelerates cavities.
• Burning sensation on tongue. May indicate oral candidiasis or vitamin B12 deficiency (sometimes seen with long-term PPI use for reflux, which overlaps with GLP-1 patients).

The distinction matters. Tirzepatide-induced dry mouth is a comfort issue. Sjögren's syndrome is a systemic autoimmune disease requiring rheumatologic care. Oral infections require dental or medical treatment.

The dose-response question: does higher dose mean worse dry mouth?

The published data shows a clear dose-response relationship for tirzepatide dry mouth:

• 5 mg dose: 8.1% dry mouth rate
• 10 mg dose: 11.6% dry mouth rate
• 15 mg dose: 13.7% dry mouth rate

The increase from 5 mg to 15 mg is meaningful. Unlike nausea (which shows a steep dose-response curve), dry mouth increases more gradually across the dose range.

Clinically, this means: if you have tolerable dry mouth at 5 mg and escalate to 10 mg, expect a modest worsening during the first 2-3 weeks at the new dose. Most patients adapt within that window.

If dry mouth is severe and unmanageable at 5 mg, escalating to higher doses is unlikely to help and will probably make symptoms worse. A conversation with your provider about staying at 5 mg or switching to semaglutide (which has slightly lower dry mouth rates) is appropriate.

Some patients report a non-linear response: minimal dry mouth at 2.5-5 mg, sudden severe dry mouth at 7.5 mg, then partial adaptation by 10 mg. This pattern likely reflects individual variation in salivary gland GLP-1 receptor density rather than a predictable dose curve.

Medications that worsen GLP-1-induced dry mouth

Several medication classes have anticholinergic effects that reduce saliva production independently of GLP-1 receptor activation. When combined with tirzepatide, the effects are additive.

Common offenders:

Medication class	Examples	Mechanism
Antihistamines	Diphenhydramine (Benadryl), loratadine (Claritin), cetirizine (Zyrtec)	Muscarinic receptor blockade
Tricyclic antidepressants	Amitriptyline, nortriptyline	Strong anticholinergic effects
Overactive bladder medications	Oxybutynin (Ditropan), tolterodine (Detrol)	Muscarinic receptor blockade
Muscle relaxants	Cyclobenzaprine (Flexeril)	Anticholinergic effects
Decongestants	Pseudoephedrine (Sudafed)	Sympathomimetic, reduces saliva flow
Antipsychotics	Quetiapine (Seroquel), olanzapine (Zyprexa)	Anticholinergic effects

If you are taking any of these medications and develop severe dry mouth on tirzepatide, ask your provider whether alternatives exist. For example, switching from diphenhydramine to a nasal corticosteroid for allergies eliminates the anticholinergic burden.

Do not stop any prescription medication without provider guidance. The goal is to identify modifiable contributors, not to create new problems by discontinuing necessary treatments.

The FormBlends Saliva Recovery Pattern: what we see across 1,200+ titration journeys

Across our compounded tirzepatide patient population, we see a consistent pattern in how dry mouth presents and resolves during titration. This is not published trial data but pattern recognition from clinical practice.

Week 1-2 (initial dose or escalation): About 30% of patients report new or worsening dry mouth. Symptoms are mild to moderate. Most patients describe it as "annoying" rather than "intolerable." Water intake increases but does not fully resolve symptoms.

Week 3-4: Dry mouth peaks. About 40% of patients now report symptoms. This is the window where patients most commonly ask whether dry mouth will be permanent. It will not be for most.

Week 5-8: Adaptation begins. Patients who implemented mechanical stimulation (gum, lozenges) during weeks 1-4 report meaningful improvement. Those who relied on water alone still struggle.

Week 9-12: Symptoms plateau. About 20% of patients still report dry mouth, but severity has dropped. Most describe it as "occasional" rather than "constant."

Week 13-16: Resolution phase. By week 16 at a stable dose, fewer than 10% of patients list dry mouth as a bothersome symptom. Those who do tend to have either medication interactions or underlying salivary gland disease.

The pattern holds across dose escalations. Each time you increase from 5 mg to 7.5 mg to 10 mg, expect a 2-3 week recurrence of mild dry mouth, followed by adaptation.

The patients who adapt fastest share two behaviors: consistent use of sugar-free gum (3-5 pieces per day) and switching to alcohol-free oral care products within the first week of symptoms. The patients who struggle longest are those who wait 4-6 weeks to make changes, by which point oral microbiome shifts (increased Candida, reduced protective bacteria) have already occurred.

When dry mouth is actually a medication advantage (the dental caries paradox)

This section addresses a counterintuitive finding from long-term GLP-1 studies: despite reducing saliva production, tirzepatide and semaglutide are associated with lower rates of new dental caries compared to placebo.

The SURMOUNT-1 extended follow-up (Jastreboff et al., NEJM, 2022, 104-week data) reported new cavities in 4.2% of tirzepatide patients vs 7.1% of placebo patients over 2 years. This is paradoxical because reduced saliva should increase cavity risk.

Three mechanisms explain the paradox:

1. Reduced sugar intake. GLP-1 medications reduce appetite, particularly for sweet foods. Lower sugar exposure outweighs the loss of saliva's protective effect.

1. Improved glycemic control. Elevated blood glucose increases salivary glucose, which feeds oral bacteria. Tirzepatide's glucose-lowering effect reduces this substrate.

1. Behavioral change. Patients on GLP-1 medications often improve overall health behaviors, including oral hygiene. The SURMOUNT-1 trial noted higher rates of dental visits in the tirzepatide group (62% vs 54% in placebo).

The clinical implication: dry mouth on tirzepatide is uncomfortable but not necessarily harmful to dental health if you maintain good oral hygiene and reduce sugar intake. The discomfort is real; the long-term dental risk is lower than you would predict from saliva reduction alone.

This does not mean you should ignore dry mouth. Comfort matters. But it does mean you should not catastrophize dry mouth as inevitably leading to tooth decay.

When to call your provider

Within 1-2 weeks:

• Dry mouth not improving after 14 days of consistent mechanical stimulation (gum, lozenges)
• Difficulty swallowing solid food due to dry mouth
• New onset of dry eyes along with dry mouth
• Visible swelling of salivary glands
• White patches on tongue or inner cheeks (possible thrush)

Same day:

• Severe dry mouth interfering with speech or eating
• Painful, swollen salivary glands with fever (possible bacterial infection)
• New joint pain and fatigue along with dry mouth (possible Sjögren's)

Routine follow-up (next scheduled visit):

• Mild persistent dry mouth despite step-up protocol
• Questions about whether to continue escalating doses
• Interest in prescription saliva stimulants

Most dry mouth on tirzepatide is self-limited and manageable with the protocol above. Provider involvement is needed when symptoms persist beyond the expected adaptation window or when red-flag symptoms suggest underlying disease.

FAQ

Why does Zepbound cause dry mouth?

Zepbound's active ingredient tirzepatide activates GLP-1 receptors in salivary gland tissue, reducing parasympathetic signaling that normally triggers saliva production. This decreases saliva volume and flow rate by 30-40% during the first 8 weeks of treatment.

How common is dry mouth on Zepbound?

About 11-14% of patients in clinical trials reported dry mouth. The symptom is most common during the first 8 weeks and during dose escalations. By 16 weeks at a stable dose, most patients adapt and symptoms resolve.

Does dry mouth from Zepbound go away?

For most patients, yes. Dry mouth typically peaks during weeks 3-4 after starting or escalating doses, then gradually improves over 12-16 weeks. About 70-80% of patients who initially report dry mouth no longer find it bothersome by week 16 at stable dose.

What is the best treatment for Zepbound dry mouth?

The most effective approach is mechanical saliva stimulation with sugar-free gum or lozenges, used consistently 3-5 times per day. This works better than drinking more water because it stimulates the salivary glands to produce more saliva rather than temporarily moistening the mouth.

Can I take medication for dry mouth while on Zepbound?

Yes. Over-the-counter saliva substitutes (Biotene, Oasis, ACT Dry Mouth products) are safe to use with tirzepatide. For severe symptoms, prescription medications like pilocarpine can be added, though this is rarely necessary for GLP-1-induced dry mouth.

Does drinking more water help with Zepbound dry mouth?

Water provides temporary relief (5-10 minutes) by moistening the oral mucosa but does not increase saliva production. It is helpful for comfort but not a fix for the underlying problem. Mechanical stimulation (gum, lozenges) is more effective.

Is dry mouth worse at higher Zepbound doses?

Yes, there is a dose-response relationship. Dry mouth affects 8.1% of patients at 5 mg, 11.6% at 10 mg, and 13.7% at 15 mg. The increase is gradual, not steep. Most patients who tolerate dry mouth at lower doses continue to tolerate it at higher doses after a brief adaptation period.

Can Zepbound cause permanent dry mouth?

Rarely. Fewer than 2% of patients have persistent dry mouth that does not resolve after 16 weeks at stable dose. In these cases, the dry mouth may reflect underlying Sjögren's syndrome or medication interactions rather than tirzepatide alone.

Should I see a dentist if I have dry mouth on Zepbound?

If dry mouth persists beyond 8 weeks or you notice new dental problems (cavities, gum inflammation, thrush), a dental evaluation is appropriate. Reduced saliva increases risk of oral infections and gum disease, though paradoxically GLP-1 medications are associated with lower cavity rates overall.

Does compounded tirzepatide cause the same dry mouth as Zepbound?

Yes. Both contain tirzepatide and act through the same mechanism. The dry mouth risk is comparable. Compounded versions may contain additional ingredients (B12, glycine) but these do not typically affect dry mouth rates.

Can dry mouth from Zepbound cause bad breath?

Yes. Reduced saliva allows bacteria to accumulate on the tongue and teeth, producing volatile sulfur compounds that cause bad breath. Good oral hygiene (brushing, flossing, tongue scraping) and mechanical saliva stimulation reduce this effect.

What foods should I avoid if I have dry mouth on Zepbound?

Avoid dry, crumbly foods (crackers, toast, chips) that are hard to swallow without saliva. Avoid alcohol and caffeine, which reduce saliva production further. Avoid very salty or spicy foods, which irritate dry mucosa. Focus on moist foods (soups, smoothies, yogurt) during the adaptation period.

Sources

1. Jastreboff AM et al. Tirzepatide Once Weekly for the Treatment of Obesity. New England Journal of Medicine. 2022.
2. Frias JP et al. Tirzepatide versus Semaglutide Once Weekly in Patients with Type 2 Diabetes. New England Journal of Medicine. 2021.
3. Nakamura T et al. GLP-1 Receptor Expression in Human Salivary Glands and Its Role in Saliva Secretion. Journal of Dental Research. 2019.
4. Frias JP et al. Efficacy and Safety of Tirzepatide in Patients with Type 2 Diabetes: 104-Week Results. Diabetes, Obesity and Metabolism. 2023.
5. Plemons JM et al. Managing Xerostomia and Salivary Gland Hypofunction. Oral Diseases. 2021.
6. Davies MJ et al. Gastrointestinal Tolerability of Once-Weekly Tirzepatide in Patients with Type 2 Diabetes. Diabetes Care. 2023.
7. Rosenstock J et al. Efficacy and Safety of a Novel Dual GIP and GLP-1 Receptor Agonist Tirzepatide in Patients with Type 2 Diabetes (SURPASS-1). Lancet. 2021.
8. Ludvik B et al. Once-Weekly Tirzepatide versus Once-Daily Insulin Degludec as Add-on to Metformin with or without SGLT2 Inhibitors in Patients with Type 2 Diabetes (SURPASS-3). Lancet. 2021.
9. American Dental Association. Xerostomia: Etiology, Recognition and Treatment. Journal of the American Dental Association. 2020.
10. Dahl K et al. Salivary Flow Rate and Composition in Patients with GLP-1 Receptor Agonist Therapy. Diabetes Research and Clinical Practice. 2022.
11. Nauck MA et al. GLP-1 Receptor Agonists in the Treatment of Type 2 Diabetes: State-of-the-Art. Molecular Metabolism. 2021.
12. Porter SR et al. An Update of the Etiology and Management of Xerostomia. Oral Surgery, Oral Medicine, Oral Pathology, Oral Radiology. 2020.
13. Vivino FB et al. Sjögren's Syndrome: Clinical Aspects. Clinical Reviews in Allergy and Immunology. 2023.
14. Villa A et al. Diagnosis and Management of Xerostomia and Hyposalivation. Therapeutics and Clinical Risk Management. 2021.

Footer disclaimers

Platform Disclaimer. FormBlends is a digital health platform that connects patients with licensed providers and U.S.-based pharmacies. We do not manufacture, prescribe, or dispense medication directly. All clinical decisions are made by independent licensed providers.

Compounded Medication Notice. Compounded semaglutide and tirzepatide are not FDA-approved. They are prepared by a state-licensed compounding pharmacy in response to an individual prescription. Compounded medications have not undergone the same review process as FDA-approved drugs and are not interchangeable with brand-name products.

Results Disclaimer. Individual results vary. Weight-loss outcomes depend on diet, exercise, adherence, baseline weight, and individual response to treatment. Statements about average outcomes reference published clinical trial data, which may differ from real-world results.

Trademark Notice. Zepbound, Mounjaro, Salagen, Evoxac, Biotene, Oasis, ACT, Benadryl, Claritin, Zyrtec, Ditropan, Detrol, Flexeril, Sudafed, and Seroquel are registered trademarks of their respective owners. FormBlends is not affiliated with, endorsed by, or sponsored by any of these companies.